Laura E. Riley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Laura E. Riley has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Adarsh Bhimraj
Division of Infectious Diseases, Houston Methodist Hospital , Houston, Texas
6 shared publications Amy Hirsch Shumaker
Department of Medicine, Case Western Reserve University, School of Medicine , Cleveland, Ohio
6 shared publicationsAmy L Dzierba
Department of Medicine, New York University Grossman School of Medicine , New York City, New York
6 shared publicationsArthur Y Kim
Harvard Medical School , Boston, Massachusetts
6 shared publicationsChristine MacBrayne
Department of Pharmacy, Children's Hospital Colorado , Aurora, Colorado
6 shared publicationsErica J Hardy
Departments of Medicine and Obstetrics and Gynecology, Brown University , Providence, Rhode Island
6 shared publications
Latest Publications
- 5 May 2026
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 8 (7) , 101982
Perceptions of respiratory syncytial virus vaccination among a publicly insured pregnant cohort
- 5 May 2026
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 8 (7) , 101982
Perceptions of respiratory syncytial virus vaccination among a publicly insured pregnant cohort
- 1 April 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (Supplement) , i18-i23
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab
This article provides a focused update to the clinical practice guideline on the treatment and management of patients with COVID-19, developed by the Infectious Diseases Society of America. The guideline panel presents a new recommendation on the use of baricitinib vs. tocilizumab in hospitalized adults with severe or critical COVID-19. The panel has previously issued recommendations on baricitinib vs. no baricitinib and tocilizumab vs. no tocilizumab, but this new recommendation compares baricitinib to tocilizumab when the decision has been made to give one or the other. The new recommendation does not address combinations of multiple immunomodulatory agents (ie, baricitinib, tocilizumab, abatacept, infliximab). The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach.
- 1 April 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (Supplement) , i18-i23
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab
This article provides a focused update to the clinical practice guideline on the treatment and management of patients with COVID-19, developed by the Infectious Diseases Society of America. The guideline panel presents a new recommendation on the use of baricitinib vs. tocilizumab in hospitalized adults with severe or critical COVID-19. The panel has previously issued recommendations on baricitinib vs. no baricitinib and tocilizumab vs. no tocilizumab, but this new recommendation compares baricitinib to tocilizumab when the decision has been made to give one or the other. The new recommendation does not address combinations of multiple immunomodulatory agents (ie, baricitinib, tocilizumab, abatacept, infliximab). The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach.
- Top Cited Papers
- 1 April 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (Supplement) , i1-i17
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults
This article provides a focused update to the clinical practice guideline on the treatment and management of people with COVID-19, developed by the Infectious Diseases Society of America. The guideline panel presents 9 updated recommendations on the use of nirmatrelvir/ritonavir, remdesivir, and molnupiravir, in adults with mild to moderate COVID-19. The recommendations are based on evidence derived from a systematic literature review and adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. The panel also provides a section on how to apply these recommendations, including an algorithm on the selection of antivirals.
- 1 April 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (Supplement) , i1-i17
Top Cited Papers2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults
This article provides a focused update to the clinical practice guideline on the treatment and management of people with COVID-19, developed by the Infectious Diseases Society of America. The guideline panel presents 9 updated recommendations on the use of nirmatrelvir/ritonavir, remdesivir, and molnupiravir, in adults with mild to moderate COVID-19. The recommendations are based on evidence derived from a systematic literature review and adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. The panel also provides a section on how to apply these recommendations, including an algorithm on the selection of antivirals.
- Open Access
- 11 March 2026
- Published by Elsevier in Journal of Obstetric, Gynecologic, & Neonatal Nursing
- Vol. 55 (5) , 485-491
Patient Activation in the Postpartum Period by Race, Ethnicity, and Spoken Language
- 11 March 2026
- Published by Elsevier in Journal of Obstetric, Gynecologic, & Neonatal Nursing
- Vol. 55 (5) , 485-491
Open AccessPatient Activation in the Postpartum Period by Race, Ethnicity, and Spoken Language
- 18 February 2026
- Published by Elsevier in Obstetrics and Gynecology Clinics of North America
- Vol. 53 (2)
Evidence, Clinical Expertise, and Research Gaps in Gender-Affirming Care
- 18 February 2026
- Published by Elsevier in Obstetrics and Gynecology Clinics of North America
- Vol. 53 (2)
Evidence, Clinical Expertise, and Research Gaps in Gender-Affirming Care
- 29 December 2025
- Published by Elsevier in Obstetrics and Gynecology Clinics of North America
- Vol. 53 (1)
The Discipline of Quality Improvement: An Imperative to Improve Women’s Health Care
- 29 December 2025
- Published by Elsevier in Obstetrics and Gynecology Clinics of North America
- Vol. 53 (1)
The Discipline of Quality Improvement: An Imperative to Improve Women’s Health Care
- 9 September 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (Supplement) , i17-i21
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept
This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019 (COVID-19), developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of abatacept in hospitalized adults with severe or critical COVID-19. The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.
- 9 September 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (Supplement) , i17-i21
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept
This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019 (COVID-19), developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of abatacept in hospitalized adults with severe or critical COVID-19. The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.
- 22 August 2025
- Published by Elsevier in Obstetrics and Gynecology Clinics of North America
- Vol. 52 (4)
The Need for Workforce Data to Inform Future Obstetrics and Gynecology Practice
- 22 August 2025
- Published by Elsevier in Obstetrics and Gynecology Clinics of North America
- Vol. 52 (4)
The Need for Workforce Data to Inform Future Obstetrics and Gynecology Practice
- 20 August 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (Supplement) , i22-i26
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab
This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019 (COVID-19), developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of infliximab in hospitalized adults with severe or critical COVID-19. The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.
- 20 August 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (Supplement) , i22-i26
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab
This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019 (COVID-19), developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of infliximab in hospitalized adults with severe or critical COVID-19. The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.
- 4 August 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (Supplement) , i1-i5
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness
As the first part of several focused updates to the clinical practice guideline on the treatment and management of COVID-19 in adults, children, and pregnant people, developed by the Infectious Diseases Society of America, the panel presents four new recommendations. These recommendations include pre-exposure prophylaxis for immunocompromised persons and treatment of severe or critical COVID-19. The panel's recommendations are based upon evidence derived from systematic literature reviews and adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach.
- 4 August 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (Supplement) , i1-i5
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness
As the first part of several focused updates to the clinical practice guideline on the treatment and management of COVID-19 in adults, children, and pregnant people, developed by the Infectious Diseases Society of America, the panel presents four new recommendations. These recommendations include pre-exposure prophylaxis for immunocompromised persons and treatment of severe or critical COVID-19. The panel's recommendations are based upon evidence derived from systematic literature reviews and adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach.